We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

By LabMedica International staff writers
Posted on 09 Jun 2025

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool. More...

With only about 20% of the eligible population regularly using FIT, researchers are exploring digital alternatives to improve uptake. Now, a new smartphone-based stool test could serve as a more convenient and patient-friendly option, potentially increasing participation in early detection efforts.

Scientists at the German Cancer Research Center (DKFZ, Heidelberg, Germany) sought to evaluate whether smartphone-based testing could meaningfully supplement traditional laboratory-based FIT screening. Their goal was to leverage everyday technology to reduce barriers and enhance accessibility for individuals hesitant to undergo standard screening procedures. The new method uses a commercially available rapid hemoglobin test paired with a smartphone app.

The process is simple: users collect a stool sample at home using a test stick, mix it in a solution, and place three drops on a test cassette. After a 15-minute wait, the test cassette is photographed using a smartphone. The app then analyzes the color intensity on the cassette to determine the presence of blood in the stool, displaying results instantly. Unlike traditional FIT, this approach eliminates the need for doctor visits, laboratory processing, and long wait times, offering a seamless, private, and immediate at-home experience.

To evaluate the effectiveness and acceptance of the smartphone test, researchers offered it to participants in the BLITZ study, who were already scheduled for colonoscopy appointments across gastroenterology practices in southern Germany between 2021 and 2023. Out of 654 participants, 361 (55%) chose to take the smartphone-based test in addition to the standard FIT. The results were promising: 89% of those who used the smartphone method rated it as a useful alternative to the conventional test, according to a standardized questionnaire.

A comparison with the colonoscopy findings showed that advanced, potentially cancerous mucosal changes were detected by the app in 28% of cases. A comparable sensitivity of 34% was determined for laboratory testing. The specificity—the second important criterion for the informative value of a diagnostic test—was 92% for both methods, suggesting a low rate of false-positive test results. This study suggests that digital tools like smartphone-based stool testing could help overcome longstanding participation barriers in colorectal cancer screening efforts. By making FIT more accessible and user-friendly, such innovations may improve early detection rates and reduce mortality associated with the disease.

“Based on our results, smartphone-based FIT testing could be a meaningful alternative or supplement to traditional laboratory tests,” said co-author Herrmann Brenner. “I see a realistic chance that this additional option will enable us to get more people on board to participate in early colon cancer detection and take advantage of the associated opportunities for colon cancer prevention.”


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Droplet Digital PCR System
QX600 AutoDG
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: INDICAID HPV Urine Test can detect 14 types of high-risk HPV using patented urine DNA concentration technology (Photo courtesy of PHASE Scientific)

World’s First Urine-Based HPV Test to Transform Cervical Cancer Screening

Human papillomavirus (HPV) is a very common sexually transmitted infection (STI) that causes more than 95% of cervical cancer cases. Detection of HPV infections that lead to cellular transformation, followed... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.